ADVM - Adverum Biotechnologies Inc
Adverum Biotechnologies Inc Logo

ADVM - Adverum Biotechnologies Inc

https://adverum.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops candidate gene therapy products to treat eye and rare diseases. The company is headquartered in Redwood City, California.

52W High
$8.56
52W Low
$1.78
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.92
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.10
EV/Revenue (<3 favorable)
117.28
P/S (TTM) (<3 favorable)
69.46
P/B (<3 favorable)
0.93
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
13.04%
Institutions (25–75% balanced)
67.50%
Shares Outstanding
20,984,200
Float
11,362,700
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
1,000,000
Gross Profit (TTM)
-109,406,000
EPS (TTM)
-8.13
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-175.13%
ROE (TTM) (>15% strong)
-2.29%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.70
Momentum
Bearish momentum
Value
0.1746
Previous
0.2147
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025